Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing study of measles and rubella antibody titers before 2nd routine immunization in L0131 participants
jRCT2031240750Completed
- Sponsor
- Research Foundation for Microbial Diseases of Osaka University
- Start
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of measles vaccine, live attenuated + rubella vaccine, live attenuated in measles and rubella, sponsored by Research Foundation for Microbial Diseases of Osaka University. Primary endpoint: Seropositive rate of neutralizing antibody against measles virus and HI antibody against rubella. Started Apr 2025; status: completed.
02
Drugs
measles vaccine, live attenuated + rubella vaccine, live attenuated
03
Conditions
measlesrubella
Beyond the preview
Go deeper on jRCT2031240750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240750.